Skip to main content

Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

A Correction to this article was published on 26 June 2020

A Correction to this article was published on 03 July 2018

This article has been updated


Immunosuppression in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by increasing risk of infections including opportunistic infections like Pneumocystis jirovecii pneumonia (PJP). Available evidence on risk factors and indications for prophylaxis in AAV is derived from PJP occurring early in the course of AAV. In this retrospective study, we characterized the profile of PJP in patients with AAV. PJP cases were identified retrospectively based on positive polymerase chain reaction test from electronic record followed by confirmation from medical records over a 10-year period. AAV patients without PJP over the same period were used as control group. Sixteen PJP+AAV+ were identified; in 14 of them, we were able to confirm they received PJP prophylaxis during induction therapy, while in two cases, data were missing. The onset of the infection was after 6 months from AAV diagnosis in 80% of cases. Escalations in immunosuppression prior to PJP were observed in six cases within 3 months prior to PJP onset. Overall mortality was 12.5%. By univariate analysis, renal involvement at AAV diagnosis was associated with PJP. These results indicate that PJP is not limited to the first 6 months following AAV diagnosis. Late-onset infection can occur in context of augmented immunotherapy, particularly with concurrent lymphopenia. Other risk factors that can independently predict late-onset PJP remain to be identified.

This is a preview of subscription content, access via your institution.

Change history

  • 03 July 2018

    The family name of the corresponding author on this article was incorrectly spelled as “El Hakem Matraiah”. The correct spelling should have been “El Hakem Metraiah”. This is now presented correctly in this article.

  • 26 June 2020

    The family name of the corresponding author on the original version of this article was incorrectly spelled as ���Mariana Philipos���.


  1. 1.

    Jennette JC (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603–606

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    McGregor JAG, Negrete-Lopez R, Poulton CJ et al (2015) Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant 30:i171–i181.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. 3.

    Kronbichler A, Jayne DRW, Mayer G (2015) Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Investig 45:346–368

    Article  CAS  Google Scholar 

  4. 4.

    Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Hoglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, for the European Vasculitis Study Group (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494.

    Article  PubMed  Google Scholar 

  5. 5.

    Grotz W, Wanner C, Rother E, Schollmeyer P (1995) Clinical course of patients with antineutrophil cytoplasm antibody positive vasculitis after kidney transplantation. Nephron 69:234–236

    Article  PubMed  CAS  Google Scholar 

  6. 6.

    Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D, EUVAS investigators (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960.

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Harper L, Savage CO (2005) ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients. Rheumatology 44:495–501.

    Article  PubMed  CAS  Google Scholar 

  8. 8.

    Wolfe RM, Peacock JE (2017) Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented? Curr Rheumatol Rep 19:35

    Article  PubMed  Google Scholar 

  9. 9.

    Morris A, Norris KA (2012) Colonization by pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 25:297–317

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. 10.

    Aasarod K, Iversen BM, Hammerstrom J et al (2000) Wegener’s granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 15:611–618

    Article  PubMed  CAS  Google Scholar 

  11. 11.

    Goupil R, Brachemi S, Nadeau ACF et al (2013) Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 8:416–423.

    Article  PubMed  CAS  Google Scholar 

  12. 12.

    Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR, Pan-Thames Renal Research Group (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776–784.

    Article  PubMed  Google Scholar 

  13. 13.

    Godeau B, Mainardi JL, Roudot-Thoraval F, Hachulla E, Guillevin L, Huong du LT, Jarrousse B, Remy P, Schaeffer A, Piette JC (1995) Factors associated with Pneumocystis carinii pneumonia in Wegener’s granulomatosis. Ann Rheum Dis 54:991–994.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. 14.

    Jones R, Harper L, Ballarin J, Blockmans D, Brogan P, Bruchfeld A, Cid M, Dahlsveen K, Dezoysa J, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Jayne D (2013) A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: “MYCYC”. On behalf of the European vasculitis study group. Presse Med 42:678–679.

    Article  Google Scholar 

  15. 15.

    Charlier C, Henegar C, Launay O, Pagnoux C, Berezne A, Bienvenu B, Cohen P, Mouthon L, Guillevin L (2009) Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 68:658–663.

    Article  PubMed  CAS  Google Scholar 

  16. 16.

    Bligny D, Mahr A, Toumelin PL et al (2004) Predicting mortality in systemic Wegener’s granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 51:83–91.

    Article  PubMed  Google Scholar 

  17. 17.

    Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594.

    Article  PubMed  CAS  Google Scholar 

  18. 18.

    Mecoli CA, Saylor D, Gelber AC, Christopher-Stine L (2017) Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. Clin Exp Rheumatol 35:671–673

    PubMed  Google Scholar 

  19. 19.

    Ogawa J, Harigai M, Nagasaka K et al (2005) Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol 15:91–96.

    Article  PubMed  CAS  Google Scholar 

  20. 20.

    Yale SH, Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc 71:5–13

    Article  PubMed  CAS  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to El Hakem Matraiah.

Ethics declarations

This study was approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.


NB and DK have received research grant from Glaxo Smith Kline for unrelated work.

The other authors have disclosed no conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Matraiah, E.H., Olisaka, N., Philipos, M. et al. Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis. Clin Rheumatol 37, 1991–1996 (2018).

Download citation


  • Anti-neutrophil cytoplasmic antibody
  • Co-trimoxazole
  • Pneumocystis jirovecii pneumonia
  • Prophylaxis
  • Vasculitis